Including the Ductal Carcinoma-In-Situ (DCIS) Score in the Development of a Multivariable Prediction Model for Recurrence After Excision of DCIS

被引:17
作者
Paszat, Lawrence [1 ,2 ,3 ]
Sutradhar, Rinku [1 ,2 ]
Zhou, Limei [2 ]
Nofech-Mozes, Sharon [1 ,3 ]
Rakovitch, Eileen [1 ,2 ,3 ]
机构
[1] Univ Toronto, T2-156 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada
[2] Inst Clin Evaluat Sci, Toronto, ON, Canada
[3] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
关键词
Ductal carcinoma in situ; Local recurrence; Multigene expression assay; Prediction model; Radiotherapy; BREAST-TUMOR RECURRENCES; RADIOTHERAPY; RISK; CANCER; SURGERY; WOMEN; OVERDIAGNOSIS; OVERTREATMENT; INDIVIDUALS; MORTALITY;
D O I
10.1016/j.clbc.2018.07.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Clinical care for women who have undergone breast-conserving surgery for ductal carcinoma-in-situ (DCIS) is controversial. Accurate prediction of the risks of recurrence would help inform decision making. Predictive models including the DCIS score multigene expression assay were developed using a complete case series of 1102 women; results indicate that such a model allows computation of more accurate risk of recurrence. Introduction: Individual prediction of local recurrence (LR) risk after breast-conserving surgery (BCS) for ductal carcinoma-in-situ (DCIS) is needed to identify women at low risk, for whom radiotherapy may be omitted. Patients and Methods: Three predictive models of LR-clinicopathologic factors (CPF) alone; CPF + estrogen receptor (ER) + human epidermal growth factor receptor 2 (HER2); and CPF + DCIS score (DS)-were developed among 1102 cases of DCIS in patients with complete covariate and outcome data. Categorizations of discrete variables and transformations of continuous variables were examined in Cox models; 2-way interactions and interactions with time were assessed. Internal validation was performed by bootstrapping. Individual predicted 10-year LR risks were computed from covariate values, estimated regression parameters, and estimated baseline survival function. Accuracy was assessed by c statistics and calibration plots. Results: The strongest prediction model incorporated CPF + DS. The c statistics for CPF + DS, CPF + ER + HER2, or CPF-alone models were 0.7025, 0.6879, and 0.6825, respectively. The CPF + DS model was better calibrated at predicting low (<= 10%) individual 10-year LR risks after BCS alone than those incorporating CPF + ER + HER2 or CPF alone, evidenced by c statistics and plots of observed by predicted risks. Among women aged >= 50 with no adverse CPF, the CPF + DS model identified the greatest proportion of women (62.3%) with predicted individual 10-year LR 10% <= without radiotherapy compared to the CPF + ER + HER2 (50.9%) or CPF alone (46.5%) models. Conclusion: Individual prediction of LR incorporating DS is more accurate and identifies a higher proportion of women with low predicted risk of LR after BCS alone, for whom radiotherapy may be omitted. (C) 2018 The Authors. Published by Elsevier Inc.
引用
收藏
页码:35 / 46
页数:12
相关论文
共 18 条
[1]  
[Anonymous], COCHRANE DATABASE SY
[2]   Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial [J].
Cuzick, Jack ;
Sestak, Ivana ;
Pinder, Sarah E. ;
Ellis, Ian O. ;
Forsyth, Sharon ;
Bundred, Nigel J. ;
Forbes, John F. ;
Bishop, Hugh ;
Fentiman, Ian S. ;
George, William D. .
LANCET ONCOLOGY, 2011, 12 (01) :21-29
[3]   Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial [J].
Donker, Mila ;
Litiere, Saskia ;
Werutsky, Gustavo ;
Julien, Jean-Pierre ;
Fentiman, Ian S. ;
Agresti, Roberto ;
Rouanet, Philippe ;
de lara, Christine Tunon ;
Bartelink, Harry ;
Duez, Nicole ;
Rutgers, Emiel J. T. ;
Bijker, Nina .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) :4054-4059
[4]   Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program [J].
Ernster, VL ;
Barclay, J ;
Kerlikowske, K ;
Wilkie, H ;
Ballard-Barbash, R .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (07) :953-958
[5]   Incidence of and treatment for ductal carcinoma in situ of the breast [J].
Ernster, VL ;
Barclay, J ;
Kerlikowske, K ;
Grady, D ;
Henderson, IC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (12) :913-918
[6]   Trends in the treatment of ductal carcinoma in situ of the breast [J].
Gotzsche, PC .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (16) :1257-1257
[7]   Precision surgery and avoiding over-treatment [J].
Hosseini, A. ;
Khoury, A. L. ;
Esserman, L. J. .
EJSO, 2017, 43 (05) :938-943
[8]   Overdiagnosis and overtreatment of breast cancer -: Progression of ductal carcinoma in situ:: the pathological perspective [J].
Jones, JL .
BREAST CANCER RESEARCH, 2006, 8 (02)
[9]   Overdiagnosis and overtreatment of breast cancer -: Rates of ductal carcinoma in situ:: a US perspective [J].
Kumar, AS ;
Bhatia, V ;
Henderson, IC .
BREAST CANCER RESEARCH, 2005, 7 (06) :271-275
[10]   RTOG 9804: A Prospective Randomized Trial for Good-Risk Ductal Carcinoma In Situ Comparing Radiotherapy With Observation [J].
McCormick, Beryl ;
Winter, Kathryn ;
Hudis, Clifford ;
Kuerer, Henry Mark ;
Rakovitch, Eileen ;
Smith, Barbara L. ;
Sneige, Nour ;
Moughan, Jennifer ;
Shah, Amit ;
Germain, Isabelle ;
Hartford, Alan C. ;
Rashtian, Afshin ;
Walker, Eleanor M. ;
Yuen, Albert ;
Strom, Eric A. ;
Wilcox, Jeannette L. ;
Vallow, Laura A. ;
Small, William, Jr. ;
Pu, Anthony T. ;
Kerlin, Kevin ;
White, Julia .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07) :709-715